


# Product Data Sheet

## LY2886721

|                  |                |
|------------------|----------------|
| <b>Cat. No.:</b> | A8465          |
| <b>CAS No.:</b>  | 1262036-50-9   |
| <b>Formula:</b>  | C18H16F2N4O2S  |
| <b>M.Wt:</b>     | 390.41         |
| <b>Synonyms:</b> |                |
| <b>Target:</b>   | Neuroscience   |
| <b>Pathway:</b>  | BACE           |
| <b>Storage:</b>  | Store at -20°C |



### Solvent & Solubility

insoluble in H<sub>2</sub>O; insoluble in EtOH; ≥19.52 mg/mL in DMSO

In Vitro

| Preparing Stock Solutions | Solvent       |  | Mass      |            |            |
|---------------------------|---------------|--|-----------|------------|------------|
|                           | Concentration |  | 1mg       | 5mg        | 10mg       |
|                           | 1 mM          |  | 2.5614 mL | 12.8070 mL | 25.6141 mL |
|                           | 5 mM          |  | 0.5123 mL | 2.5614 mL  | 5.1228 mL  |
|                           | 10 mM         |  | 0.2561 mL | 1.2807 mL  | 2.5614 mL  |

Please refer to the solubility information to select the appropriate solvent.

### Biological Activity

Shortsummary

BACE inhibitor

IC<sub>50</sub> & Target

In Vitro

#### Cell Viability Assay

Preparation method:

In Vivo

#### Animal experiment

Animal models: PDAPP mice

Dosage form: 3, 10 or 30 mg/kg; p.o.

Applications: At all 3 doses, LY2886721 significantly reduced hippocampal and cortical

levels of A $\beta$ 1-x. In addition, LY2886721 significantly lowered brain parenchymal levels of C99 and sAPP $\beta$ . Although cortical levels of C99 were reduced significantly by LY2886721 at the doses of 10 and 30 mg/kg, the effect of LY2886721 at the dose of 3 mg/kg failed to reach statistical significance. On the other hand, the sAPP $\beta$  levels were significantly decreased by LY2886721 at all 3 doses.

Other notes:

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

1. Audrain M, Souchet B, et al. " $\beta$ APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease." *Cereb Cortex*. 2017 Oct 18:1-18. PMID:29048465

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ. The potent BACE1 inhibitor LY2886721 elicits robust central A $\beta$  pharmacodynamic responses in mice, dogs, and humans. *J Neurosci*. 2015 Jan 21;35(3):1199-210.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

*Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.*



---

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

